Sponsor or institution

Clinical trials and research at Stichting Hemato-Oncologie voor Volwassenen Nederland

• 10Clinical trials
• 19Countries

Newest trials

All recruiting trials (10)

• Bleximenib with standard induction/consolidation chemotherapy followed by maintenance for newly diagnosed AML with NPM1 or KMT2A changes

  This trial will test whether adding bleximenib to standard chemotherapy and maintenance helps adults with newly diagnosed AML who have NPM1 mutations or KMT2A rearrangements.

  Recruiting at 108 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · Los Angeles, California and 107 other locations · NCT07223814

• Ivosidenib and azacitidine with or without venetoclax for adults with newly diagnosed IDH1‑mutated AML who are not candidates for intensive chemotherapy

  This trial tests whether adding venetoclax to ivosidenib plus azacitidine helps adults with newly diagnosed IDH1‑mutated AML who are not able to receive intensive chemotherapy.

  Recruiting at 2 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · Feldkirch and 118 other locations · NCT07075016

• Combining revumenib with azacitidine and venetoclax for treating specific types of acute myeloid leukemia

  This study is testing a new combination of medications to see if it can help people with specific types of acute myeloid leukemia who can't have intensive chemotherapy.

  Recruiting at 128 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · Los Angeles, California and 200 other locations · NCT06652438

• Tasquinimod treatment for patients with myelofibrosis who can't tolerate JAK inhibitors

  This study is testing if tasquinimod can be a safe and effective treatment for people with myelofibrosis who can't tolerate JAK inhibitors.

  Recruiting Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Aachen and 5 other locations · NCT06605586

• Preventing heart damage in lymphoma patients receiving chemotherapy

  This study is testing if a drug called dexrazoxane can help prevent heart damage in adults with lymphoma who are receiving chemotherapy.

  Recruiting at 25 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · 's-Hertogenbosch and 24 other locations · NCT06220032

• Evaluating a treatment-free interval for newly diagnosed multiple myeloma patients

  This study is testing if taking a break from treatment can help newly diagnosed multiple myeloma patients manage their disease while feeling better and having fewer side effects.

  Recruiting at 38 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · 's-Hertogenbosch and 37 other locations · NCT06187441

• Assessing a new treatment for older patients with acute myeloid leukemia

  This study is testing a new combination of medications for older adults newly diagnosed with acute myeloid leukemia to see if it can improve treatment while lowering costs.

  Recruiting at 19 sites Phase 2 Stichting Hemato-Oncologie voor Volwassenen Nederland · 's-Hertogenbosch and 18 other locations · NCT06014489

• Combining venetoclax with epcoritamab for treating relapsed or refractory CLL or SLL

  This study is testing a new combination of two treatments, venetoclax and epcoritamab, to see if they can help people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) feel better.

  Recruiting at 25 sites Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Melbourne and 28 other locations · NCT05791409

• Retreatment with venetoclax and acalabrutinib for relapsed CLL

  This study is testing if a new combination of venetoclax and acalabrutinib can help people with relapsed chronic lymphocytic leukemia (CLL) achieve better treatment results after their previous therapy.

  Recruiting at 18 sites Phase 2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Brussels and 17 other locations · NCT04523428

• Treatment for CD30 Positive Diffuse Large B-cell Lymphoma Patients Who Didn't Respond to Initial Chemotherapy

  This study is testing a new treatment combining brentuximab vedotin and chemotherapy for patients with CD30 positive diffuse large B-cell lymphoma who didn't respond to their first chemotherapy, to see if it can improve their chances of recovery.

  Recruiting Phase 1/2 Stichting Hemato-Oncologie voor Volwassenen Nederland · Rotterdam · NCT03356054

Quick answers

How many clinical trials run by Stichting Hemato-Oncologie voor Volwassenen Nederland are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 19 countries. The most sites are in Netherlands (10 trials), Germany (5 trials), Belgium (5 trials), Denmark (4 trials), Australia (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 1/2: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →